Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Abstract

These observations suggest that cotargeting cyclin and MEK signaling can be successful when tumors bear genomic coalterations that activate both of these pathways. Further prospective studies using this matching precision strategy to overcome resistance are warranted.<i>See related commentary by Groisberg and Subbiah, p. 2672</i>.